While formal clinical trials of this specific combination await development, the theoretical basis for synergy is compelling, supported by successful precedents like CagriSema and the impressive individual performance of both compounds
In Phase 1, the focus is on clearing the overgrowth using antimicrobials, restrictive diets and digestive supports to reduce symptoms and lower gas levels
Topical and Injectable GHK-Cu Routes Compared Topical GHK-Cu has published cosmetic, wound, and trial-context evidence, while injectable GHK-Cu lacks an FDA-approved dosing label and is specifically discussed by FDA in relation to compounded injectable safety concerns [2], [3], [7], [8]
The gap between animal research and proven human therapies remains significant
Any intervention that addresses these fundamental challenges holds promise for improving outcomes
Shimizu T, Numata T, Okada Y